Stephen V Liu: Retrospective report on treatment post osimertinib for EGFR NSCLC

Stephen V Liu shared a post on X, about recent paper published in Clinical Lung Cancer:

Treatment patterns and clinical outcomes in patients with EGFR-mutated non-small cell lung cancer after progression on osimertinib.

Authors: Nathaniel D. Robinson, Maureen E. Canavan, Peter L. Zhan, Brooks V. Udelsman, Ranjan Pathak, Daniel J. Boffa, Sarah B. Goldberg.

”Retrospective report on treatment post osimertinib for EGFR non-small cell lung cancer (NSCLC) at Clinical Lung Cancer (n=538). 65% had chemotherapy, 37% had immunotherapy, 44% had tyrosine kinase inhibitor (TKI). Here, in patients receiving chemotherapy, continuation of osimertinib associated with better outcomes, especially del19.

Conflicting reports regarding value of continuing osimertinib and many confounders with retrospective analyses – prospective COMPEL study will be important to define the space, but my current off-study standard is MARIPOSA-2.”

Source: Stephen V Liu/X

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.